Abstract
AimTo assess if sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) reduce the risk of all‐cause mortality, cardiovascular death and hospitalization for heart failure (HF) or chronic kidney disease (CKD) to a greater extent than dipeptidyl peptidase‐4 inhibitors (DPP4is) in people with type 2 diabetes (T2D) with or without established cardiovascular and/or renal disease (CVRD).MethodsThis retrospective cohort study propensity‐matched 24 438 patients receiving an SGLT2i 1:1 to a patient receiving a DDP4i, stratified based on the presence of CVRD. The primary outcomes were the time to each of the following: all‐cause mortality, cardiovascular death or hospitalization for HF, myocardial infarction, stroke and CKD.ResultsOverall, SGLT2is were associated with reductions in all‐cause mortality, cardiovascular mortality, hospitalization for HF and hospitalization for CKD compared with DPP4is. In patients with no CVRD history, SGLT2is were associated with reductions in all‐cause mortality (HR 0.71, 95% CI 0.57‐0.88; P = .002), hospitalization for HF (HR 0.76, 95% CI 0.59‐0.98; P = .035) and hospitalization for CKD (HR 0.75, 95% CI 0.63‐0.88; P < .001). In patients with established cardiovascular disease (CVD) or at high risk, SGLT2is were associated with reductions in all‐cause mortality (HR 0.69, 95% CI 0.59‐0.82; P < .001), cardiovascular mortality (HR 0.76, 95% CI 0.62‐0.95; P = .014), hospitalization for HF (HR 0.73, 95% CI 0.63‐0.85; P < .001), hospitalization for stroke (HR 0.75, 95% CI 0.59‐0.94; P = .013) and hospitalization for CKD (HR 0.49, 95% CI 0.43‐0.54; P < .001).ConclusionThere was consistency across subgroups and sensitivity analyses. SGLT2is were associated with a reduced risk of all‐cause mortality and hospitalization for HF and CKD compared with DPP4‐is, highlighting the need to introduce SGLT2is early in the management of patients with T2D.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.